Clinical Trial: Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07162480) titled 'Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)' on Aug. 31.

Brief Summary: Phase II open label study designed to evaluate the efficacy and safety of P-Sam in patients with aggressive, solid, NOTCH mutant or p63 low (B7-H4 high) R/M ACC-I patients.

Study Start Date: Feb. 28, 2026

Study Type: INTERVENTIONAL

Condition: Adenoid Cystic Carcinoma

Intervention: DRUG: P-Sam

Given by IV

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderson Cancer Center

Published by HT Digital Content Services with permission from Health Dail...